At Daiichi Sankyo we aim to create essential medicine for longer, better lives. The core and catalyst behind our oncology development plan is our DXd ADC Technology. ADCs, or antibody drug conjugates, are therapies that combine 3 components—an antibody connected to a payload via a linker.
What makes Daiichi Sankyo’s DXd ADC Technology unique is our linker and payload. Explore the origins behind Daiichi Sankyo’s proprietary DXd ADC Technology and learn how this innovative approach provides targeted cancer therapy through our new video series: The Making of DXd ADC.
Looking Towards the Future of Oncology:
Ken Keller, Global Head of the Oncology Business, explores the organization’s goals with DXd ADC Technology and how Daiichi Sankyo seeks to go beyond making incremental differences, by striving to create new standards of care for people with cancer around the world.
Discover the Design Behind DXd Antibody Drug Conjugates (ADCs):
Mark Rutstein, Global Head of Oncology Clinical Development, discusses the linker-payload, the core of Daiichi Sankyo’s DXd ADC Technology. He discusses how the traits of DXd ADC Technology aim to help patients with unmet medical needs.
Suggestions
In certain cancers, HER2 becomes overexpressed or uncontrolled, driving tumors to develop quickly. As our understanding of HER2 and its role deepens, its relevance across endometrial, ovarian and other gynecologic tumors has become…
My decision to devote my career to oncology is deeply personal. During my senior year in college, my father was diagnosed with cholangiocarcinoma, or bile duct cancer. As one of his caregivers…
Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.